Phase 2
N=88
Anastrozole Administration in Elderly Hypogonadal Men
Hypogonadism
Bottom Line
View on ClinicalTrials.gov: NCT00136695 ↗Enrolled (actual)
88
Serious AEs
7.2%
Results posted
Jan 2017
Primary outcome: Primary: Change in Lean Body Mass — -2000; -1500 grams
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- anastrozole (Drug)
- Age
- Adult, Older Adult · 60+ yrs
- Sex
- Male
- Sponsor
- Massachusetts General Hospital
- Primary completion
- Oct 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Lean Body Mass |
-2000; -1500 | — |
Summary
The purpose of the study is to assess the effects of sustained aromatase inhibitor therapy to reduce estrogen levels in elderly men with mild hypogonadism (a decreased level of sex hormones).
Eligibility Criteria
Inclusion Criteria
- Men ages 60 and older
- Serum testosterone between 150-300 ng/dL
- Symptoms suggestive of androgen deficiency
Data sourced from ClinicalTrials.gov (NCT00136695). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.